视神经脊髓炎谱系疾病合并疼痛抑郁共病综述

doi:10.24920/003859

Abstract

Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory disorder of the central nervous system predominantly targeting optic nerves and the spinal cord. The prevalence of the disease is much higher in Asia than in other parts of the world. Pain can be detected in more than 80% of NMOSD patients, with evoked pain mostly being caused by painful tonic muscle spasms and neuropathic pain as the most characteristic types. Depression is often comorbid with pain, and their comorbidity can severely influence quality of life. In recent years, studies have found considerable overlaps between the mechanisms of pain and depression; however, their association remains unclear. This article reviews the epidemiology, mechanism, evaluation and treatment of pain-depression comorbidity in NMOSD patients.

Key words: neuromyelitis optica spectrum disorder, pain, depression, comorbidity

Xue Zhang, Yan Xu, Lijian Pei. Review of Neuromyelitis Optica Spectrum Disorder with Pain-Depression Comorbidity[J].Chinese Medical Sciences Journal, 2021, 36(4): 316-322.

Figures/Tables 1

References 54.

1.	Cabrera-Gómez JA, Kurtzke JF, González-Quevedo A, et al. An epidemiological study of neuromyelitis optica in Cuba. J Neurol 2009; 256(1):35-44. doi: 10.1007/s00415-009-0009-0. doi: 10.1007/s00415-009-0009-0 pmid: 19224310
2.	Asgari N, Lillevang ST, Skejoe HP, et al. A population-based study of neuromyelitis optica in Caucasians. Neurology 2011; 76(18):1589-95. doi: 10.1212/ 10.1212/WNL.0b013e3182190f74. doi: 10.1212/WNL.0b013e3182190f74 pmid: 21536639
3.	Flanagan EP, Cabre P, Weinshenker BG, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol 2016; 79(5):775-83. doi: 10.1002/ana.24617. doi: 10.1002/ana.24617 pmid: 26891082
4.	Bukhari W, Prain KM, Waters P, et al. Incidence and prevalence of NMOSD in Australia and New Zealand. J Neurol Neurosurg Psychiatry 2017; 88(8):632. doi: 10.1136/jnnp-2016-314839. doi: 10.1136/jnnp-2016-314839 pmid: 28550069
5.	Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364(9451):2106-12. doi: 10.1016/S0140-6736(04)17551-X. doi: 10.1016/S0140-6736(04)17551-X pmid: 15589308
6.	Jarius S1, Wildemann B. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol 2013; 23(6):661-83. doi: 10.1111/bpa.12084. doi: 10.1111/bpa.12084
7.	Bennett JL, Lam C, Kalluri SR, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009; 66(5):617-29. doi: 10.1002/ana.21802. doi: 10.1002/ana.21802
8.	Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009; 66(5):630-43. doi: 10.1002/ana.21837. doi: 10.1002/ana.21837
9.	Huang W, Zhang Bao J, Chang X, et al. Neuromyelitis optica spectrum disorder in China: quality of life and medical care experience. Mult Scler Relat Disord 2020; 46:102542. doi: 10.1016/j.msard.2020.102542. doi: 10.1016/j.msard.2020.102542
10.	Pellkofer HL, Havla J, Hauer D, et al. The major brain endocannabinoid 2-AG controls neuropathic pain and mechanical hyperalgesia in patients with neuromyelitis optica. PLoS One 2013; 8(8):e71500. doi: 10.1371/journal.pone.0071500. doi: 10.1371/journal.pone.0071500
11.	Asseyer S, Schmidt F, Chien C, et al. Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders. Mult Scler J Exp Transl Clin 2018; 4(3):2055217318796684. doi: 10.1177/2055217318796684. doi: 10.1177/2055217318796684
12.	Zhao S, Mutch K, Elsone L, et al. Neuropathic pain in neuromyelitis optica affects activities of daily living and quality of life. Mult Scler 2014; 20(12):1658-61. doi: 10.1177/1352458514522103. doi: 10.1177/1352458514522103
13.	Kong Y, Okoruwa H, Revis J, et al. Pain in patients with transverse myelitis and its relationship to aquaporin 4 antibody status. J Neurol Sci 2016; 368:84-8. doi: 10.1016/j.jns.2016.06.041. doi: 10.1016/j.jns.2016.06.041
14.	Chavarro VS, Mealy MA, Simpson A, et al. Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm 2016; 3(6):e286. doi: 10.1212/NXI.0000000000000286. doi: 10.1212/NXI.0000000000000286
15.	Brody J, Hellmann MA, Marignier R, et al. Neuromyelitis optica spectrum disorder: disease course and long-term visual outcome. J Neuroophthalmol 2016; 36(4):356-62. doi: 10.1097/WNO.0000000000000403. doi: 10.1097/WNO.0000000000000403
16.	Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016; 13(1):280. doi: 10.1186/s12974-016-0718-0. doi: 10.1186/s12974-016-0718-0
17.	Masuda H, Mori M, Uzawa A, et al. Validation of the Modified Fatigue Impact Scale and the relationships among fatigue, pain and serum interleukin-6 levels in patients with neuromyelitis optica spectrum disorder. J Neurol Sci 2018; 385:64-8. doi: 10.1016/j.jns.2017.11.041. doi: 10.1016/j.jns.2017.11.041
18.	Mealy MA, Boscoe A, Caro J, et al. Assessment of patients with neuromyelitis optica spectrum disorder using the EQ-5D. Int J MS Care 2019; 21(3):129-34. doi: 10.7224/1537-2073.2017-076. doi: 10.7224/1537-2073.2017-076
19.	Chanson JB, Zéphir H, Collongues N, et al. Evaluation of health-related quality of life, fatigue and depression in neuromyelitis optica. Eur J Neurol 2011; 18(6):836-41. doi: 10.1111/j.1468-1331.2010.03252.x. doi: 10.1111/j.1468-1331.2010.03252.x pmid: 21087360
20.	Seok JM, Choi M, Cho EB, et al. Fatigue in patients with neuromyelitis optica spectrum disorder and its impact on quality of life. PLoS One 2017; 12(5):e0177230. doi: 10.1371/journal.pone.0177230. doi: 10.1371/journal.pone.0177230
21.	Qian P, Lancia S, Alvarez E, et al. Association of neuromyelitis optica with severe and intractable pain. Arch Neurol 2012; 69(11):1482-7. doi: 10.1001/ archneurol.2012.768. doi: 10.1001/ archneurol.2012.768
22.	Kanamori Y, Nakashima I, Takai Y, et al. Pain in neuromyelitis optica and its effect on quality of life: a cross-sectional study. Neurology 2011; 77(7):652-8. doi: 10.1212/WNL.0b013e318229e694 pmid: 21813781
23.	Eaneff S, Wang V, Hanger M, et al. Patient perspectives on neuromyelitis optica spectrum disorders: data from the PatientsLikeMe online community. Mult Scler Relat Disord 2017; 17:116-22. doi: 10.1212/WNL.0b013e318229e694. doi: 10.1212/WNL.0b013e318229e694
24.	Kim SM, Go MJ, Sung JJ, et al. Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility, and clinical characteristics. Arch Neurol 2012; 69(8):1026-31. doi: 10.1001/archneurol.2012.112. doi: 10.1001/archneurol.2012.112
25.	Bradl M, Kanamori Y, Nakashima I, et al. Pain in neuromyelitis optica-prevalence, pathogenesis and therapy. Nat Rev Neurol 2014; 10(9):529-36. doi: 10.1038/nrneurol.2014.129. doi: 10.1038/nrneurol.2014.129
26.	Mealy MA, Kozachik SL, Levy M. Review of treatment for central spinal neuropathic pain and its effect on quality of life: implications for neuromyelitis optica spectrum disorder. Pain Manag Nurs 2019; 20(6):580-91. doi: 10.1016/j.pmn.2019.03.003. doi: 10.1016/j.pmn.2019.03.003
27.	Beekman J, Keisler A, Pedraza O, et al. Neuromyelitis optica spectrum disorder: patient experience and quality of life. Neurol Neuroinflamm 2019; 6(4):e580. doi: 10.1212/NXI.0000000000000580. doi: 10.1212/NXI.0000000000000580
28.	Misu T, Höftberger R, Fujihara K, et al. Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol 2013; 125(6):815-27. doi: 10.1007/ s00401-013-111٦-7. doi: s00401-013-111
29.	Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 2002; 125(Pt 7):1450-61. doi: 10.1093/brain/awf151. doi: 10.1093/brain/awf151 pmid: 12076996
30.	Ikeda H, Stark J, Fischer H, et al. Synaptic amplifier of inflammatory pain in the spinal dorsal horn. Science 2006; 312(5780):1659-62. doi: 10.1126/science. 1127233. doi: 10.1126/science. 1127233
31.	Drdla R, Gassner M, Gingl E, et al. Induction of synaptic long-term potentiation after opioid withdrawal. Science 2009; 325(5937):207-10. doi: 10.1126/science.1171759 pmid: 19590003
32.	Hinson SR, Roemer SF, Lucchinetti CF, et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med 2008; 205(11):2473-81. doi: 10.1126/science.1171759. doi: 10.1126/science.1171759
33.	Marignier R, Nicolle A, Watrin C, et al. Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain 2010; 133(9):2578-91. doi: 10.1093/brain/awq177. doi: 10.1093/brain/awq177 pmid: 20688809
34.	Moga D, Hof PR, Vissavajjhala P, et al. Parvalbumin-containing interneurons in rat hippocampus have an AMPA receptor profile suggestive of vulnerablility to excitotoxicity. J Chem Neuroanat 2002; 23(4):249-53. doi: 10.1016/s0891-0618(02)00012-1. doi: 10.1016/s0891-0618(02)00012-1
35.	Zeilhofer HU, Wildner H, Yévenes GE. Fast synaptic inhibition in spinal sensory processing and pain control. Physiol Rev 2012; 92(1):193-235. doi: 10.1152/physrev.00043.2010. doi: 10.1152/physrev.00043.2010 pmid: 22298656
36.	Janssen SP, Truin M, Van Kleef M, et al. Differential GABAergic disinhibition during the development of painful peripheral neuropathy. Neuroscience 2011; 184:183-94. doi: 10.1016/j.neuroscience. 2011.03.060. doi: 10.1016/j.neuroscience.2011.03.060 pmid: 21496475
37.	Moore KA, Kohno T, Karchewski LA, et al. Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord. J Neurosci 2002; 22(15):6724-31. doi: 10.1523/JNEUROSCI.22-15-06724.2002. doi: 10.1523/JNEUROSCI.22-15-06724.2002
38.	Albrecht J, Sidoryk-Węgrzynowicz M, Zielińska M, et al. Roles of glutamine in neurotransmission. Neuron Glia Biol 2010; 6(4):263-76. doi: 10.1017/S1740925X11000093. doi: 10.1017/S1740925X11000093 pmid: 22018046
39.	Basbaum AI, Bautista DM, Scherrer G, et al. Cellular and molecular mechanisms of pain. Cell 2009; 139(2):267-84. doi: 10.1016/j.cell.2009.09.028. doi: 10.1016/j.cell.2009.09.028 pmid: 19837031
40.	Rayner L, Hotopf M, Petkova H, et al. Depression in patients with chronic pain attending a specialised pain treatment centre: prevalence and impact on health care costs. Pain 2016; 157(7):1472-9. doi: 10.1097/j.pain.0000000000000542. doi: 10.1097/j.pain.0000000000000542
41.	Mitchell ND, Baker GB. An update on the role of glutamate in the pathophysiology of depression. Acta Psychiatr Scand 2010; 122(3):192-210. doi: 10.1111/j.1600-0447.2009.01529.x. doi: 10.1111/j.1600-0447.2009.01529.x
42.	Hashimoto K. The role of glutamate on the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35(7):1558-68. doi: 10.1016/j.pnpbp.2010.06.013. doi: 10.1016/j.pnpbp.2010.06.013
43.	Pehrson AL, Sanchez C. Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants. Drug Des Devel Ther 2015; 9:603-24. doi: 10.2147/DDDT.S62912. doi: 10.2147/DDDT.S62912
44.	Kanes S, Colquhoun H, Gunduz-Bruce H, et al. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet 2017; 390(10093):480-9. doi: 10.1016/S0140-6736(17)31264-3. doi: 10.1016/S0140-6736(17)31264-3
45.	Benson C, Mifflin K, Kerr B, et al. Biogenic amines and the amino acids GABA and glutamate: relationships with pain and depression. Mod Trends Pharmacopsychiatry 2015; 30:67-79. doi: 10.1159/000435933. doi: 10.1159/000435933
46.	Goffer Y, Xu D, Eberle SE, et al. Calcium-permeable AMPA receptors in the nucleus accumbens regulate depression-like behaviors in the chronic neuropathic pain state. J Neurosci 2013; 33(48):19034-44. doi: 10.1523/JNEUROSCI.2454-13.2013. doi: 10.1523/JNEUROSCI.2454-13.2013
47.	Sałat K, Podkowa A, Malikowska N, et al. Novel, highly potent and in vivo active inhibitor of GABA transporter subtype 1 with anticonvulsant, anxiolytic, antidepressant and antinociceptive properties. Neuropharmacology 2017; 113(Pt A):331-42. doi: 10.1016/j. neuropharm.2016.10.019. doi: 10.1016/j. neuropharm.2016.10.019
48.	Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromye- litis optica spectrum disorders. Neurology 2015; 85(2):177-89. doi: 10.1212/WNL.0000000000001729. doi: 10.1212/WNL.0000000000001729 pmid: 26092914
49.	Abboud H, Petrak A, Mealy M, et al. Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange. Mult Scler 2016; 22(2):185-92. doi: 10.1177/1352458515581438. doi: 10.1177/1352458515581438
50.	Watanabe S, Nakashima I, Misu T, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007; 13(1):128-32. doi: 10.1177/1352458506071174. doi: 10.1177/1352458506071174
51.	Elsone L, Panicker J, Mutch K, et al. Role of intravenous immunoglobin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler 2014; 20(4):501-4. doi: 10.1177/1352458513495938. doi: 10.1177/1352458513495938
52.	Selmaj K, Selmaj I. Novel emerging treatments for NMOSD. Neurol Neurochir Pol 2019; 53(3):317-26. doi: 10.5603/PJNNS.a2019.0049. doi: 10.5603/PJNNS.a2019.0049
53.	Butler S. The triumvirate of co-morbid chronic pain, depression, and cognitive impairment: attacking this “chicken-and-egg” in novel ways. Scand J Pain 2017; 15:148-9. doi: 10.1016/j.sjpain.2017.03.004. doi: 10.1016/j.sjpain.2017.03.004
54.	Mealy MA, Kozachik SL, Cook LJ, et al. Scrambler therapy improves pain in neuromyelitis optica: a randomized controlled trial. Neurology 2020; 94(18):e1900-7. doi: 10.1212/WNL.0000000000009370. doi: 10.1212/WNL.0000000000009370

Name of scales	Characteristics
Pain assessment scales
NRS	Pain severity evaluation
DN4	Screening NeP
LANSS	Self-reported by patients, screening NeP
BPI	Overall assessment of pain, including severity, location, nature, and relief degree after treatment
NPSI	NeP symptom evaluation
Depression assessment scales
BDI	Most widely used depression evaluation scale
PHQ-9	High sensitivity and specificity in screening depression in patients with chronic pain
SDS-Zung	Can be finished within 5 min, easy to use
HADS	Used for the evaluation of anxiety and depression
Quality of life assessment scales
SF-36	Most widely used evaluation of HRQoL
MSQoL	Specific evaluation scale for HRQoL in MS and NMOSD patients
GJCF-NMOSD	Specific evaluation scale for HRQoL in MS and NMOSD patients

[1]	Jianbo Xiu, Lanlan Li, Qi Xu. Minocycline Activates the Nucleus of the Solitary Tract-Associated Network to Alleviate Lipopolysaccharide-Induced Neuroinflammation [J]. Chinese Medical Sciences Journal, 2022, 37(1): 1-14.
[2]	Cai Cui,Xu Changqing,Jin Hualiang,Li Bei. Combined Effects of Chronic Obstructive Pulmonary Disease and Depression on Spatial Memory in Old Rats [J]. Chinese Medical Sciences Journal, 2018, 33(4): 260-266.
[3]	Che Lu, Lu Xin, Pei Li-jian. Efficacy and Safety of a Continuous Wound Catheter in Open Abdominal Partial Hepatectomy [J]. Chinese Medical Sciences Journal, 2017, 32(3): 171-176.
[4]	Dhungana Hemanta, Xiao-xing Jiang, Zhen-zhou Feng, Zi-xian Chen, Yuan-wu Cao. Etiology for Degenerative Disc Disease [J]. Chinese Medical Sciences Journal, 2016, 31(3): 185-191.
[5]	Yu-ping Mo,Hai-jiang Yao,Hong-tao Song,An-ping Xu,Yin-shan Tang,Zhi-gang Li^*. Progress of Animal Research on Electro-acupuncture Treatment for Depression [J]. Chinese Medical Sciences Journal, 2014, 29(1): 43-47.
[6]	Kang-sheng Liu, Jia-hu Hao, Yu-qing Xu, Xiao-qi Gu, Juan Shi, Chun-fang Dai, Fei Xu, and Rong Shen. Breast Milk Lead and Cadmium Levels in Suburban Areas of Nanjing, China [J]. Chinese Medical Sciences Journal, 2013, 28(1): 7-15.
[7]	Le Shen, Xu Li, Wen Chen, Li Xu, Wei Liu, Xue-rong Yu, and Yu-guang Huang. PSD95 Gene Specific siRNAs Attenuate Neuropathic Pain through Modulating Neuron Sensibility and Postsynaptic CaMKIIα Phosphorylation [J]. Chinese Medical Sciences Journal, 2011, 26(4): 201-207.
[8]	Wen-min Tian, Ke-rang Zhang, Juan Zhang, Yan Shen and Qi Xu. Association between the Epidermal Growth Factor Gene and Intelligence in Major Depression Patients [J]. Chinese Medical Sciences Journal, 2010, 25(2): 105-108.

Early edition

Current issue

Archive

Specialties & Topics

Author center

Reviewer center

Review of Neuromyelitis Optica Spectrum Disorder with Pain-Depression Comorbidity

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 54.

Related Articles 8

Metrics

Recommended 10